[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
July 1997

Antineoplastic Chemotherapy, Sweat, and the Skin

Author Affiliations

Departments of Dermatology, Pathology, and Oncology The Johns Hopkins Medical Institutions 600 N Wolfe St, Blalock 920 Baltimore, MD 21297

Arch Dermatol. 1997;133(7):905-906. doi:10.1001/archderm.1997.03890430123017
Abstract

TREATMENT FOR cancer is becoming increasingly complicated. New classes of drugs and innovative approaches to therapy involving immunologic manipulation have resulted in fascinating side effects in the skin. In many instances, these side effects are referable to a specific agent and result in increased understanding of the pathophysiologic changes of the skin. In this issue, Valks et al1 report the clinicopathologic correlation between the histologic finding of eccrine squamous syringometaplasia (ESS) and the cutaneous eruptions sampled from 10 patients receiving high-dose antineo-plastic chemotherapy with bone marrow or peripheral blood stem cell support in the treatment of various malignant neoplasms. These observations highlight the connection between the concentration of antineoplastic medications in eccrine sweat and subsequent clinical and histologic changes in the skin.

The secretory portion of the eccrine apparatus produces an isotonic to slightly hypertonic fluid, which becomes increasingly concentrated as water is removed with the passage of the

First Page Preview View Large
First page PDF preview
First page PDF preview
×